about
Unmet medical needs in systemic lupus erythematosusA proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis TrialDefining Low Disease Activity in Systemic Lupus Erythematosus.Effects of the Sri Lankan medicinal plant, Salacia reticulata, in rheumatoid arthritis.Anti-proliferative effects of Salacia reticulata leaves hot-water extract on interleukin-1β-activated cells derived from the synovium of rheumatoid arthritis model miceSystemic lupus erythematosus: review of synthetic drugs.Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus CohortA systematic review of prevalence, disease characteristics and management of systemic lupus erythematosus in Australia: identifying areas of unmet need.Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritisChinese Herbal Medicine (Zi Shen Qing) for Mild-to-Moderate Systematic Lupus Erythematosus: A Pilot Prospective, Single-Blinded, Randomized Controlled Study.2013 update: Hopkins lupus cohort.Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.Independent association of glucocorticoids with damage accrual in SLE.The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus ManifestationLack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV.The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness.Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.Development of the Systemic Lupus Erythematosus Steroid Questionnaire (SSQ): a novel patient-reported outcome tool to assess the impact of oral steroid treatment.To what extent can preventive treatments prevent damage from systemic lupus erythematosus?Glucocorticoid use and abuse in SLE.Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies.Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight.Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial.The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years?Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids.Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review.Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.Remission and withdrawal of therapy in lupus nephritis.Rethinking biologics in lupus nephritis.Why targeted therapies are necessary for systemic lupus erythematosus.It hasn't gone away: the problem of glucocorticoid use in lupus remains.Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.Burden of systemic glucocorticoid-related complications in severe asthma.Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid non-associated organ damage.Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study.Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus.Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort.
P2860
Q27005906-3E6EAFC7-39F7-42B7-A8EA-098C5646DD0FQ31029893-8901A408-84A1-43E7-9B80-2150FF636E66Q33435736-B37F0ED7-DABA-4064-97F3-109D55A61D39Q33646002-2EB52056-070C-44FE-AB9E-D739591CEC1FQ34248497-8787FFF3-33A4-45CF-9D5B-90A1301F7DB7Q34498515-44887875-8956-43AD-8585-8F4B23FEE058Q35229284-171E900B-C498-4765-B069-55C06960AF9AQ35234558-ABDEDBF3-DDD2-4C34-8167-EC7E3CF55ED4Q35803646-2DF1BBC7-F2C2-4B18-9682-10934CF2B534Q36681801-2F9F2478-11EF-4882-B187-C8D269471CD5Q36869519-889DF02C-D860-43C8-8C47-C8D9D9721751Q37131283-F7A2C020-7351-4AE8-B661-3D20786A128CQ37456307-7FF37666-B79E-4E7D-85F5-0DB02F61B402Q37464030-71B58A79-E261-4C38-80D1-B2A785144F1DQ37511805-9F77BC18-51A3-418D-A843-C19164E941F1Q37586440-707F9EBA-D258-4A21-9ADE-2304E7C31764Q37627356-65ADA231-4ACA-4BF7-A194-E02156AE7519Q37633396-14325DE9-98A9-4BAA-9ABC-800408560D8DQ37673352-94E5E4AE-E850-4FC5-A4FB-5E269F3FF72CQ37879597-E78C8FA8-A141-4E54-B7EA-00046ADD7A0FQ37978291-5A942AF1-8C39-4A2C-AADC-A2FCE0AA6B05Q38205079-FAE6DD8A-A4A5-4E45-980E-F67D74304DD6Q38289398-79A98884-5AAE-405E-8902-A67FFF5178D9Q38388428-9A971DD3-D996-4C39-961F-9CF443703A69Q38598128-5AE05ECD-47CC-4DD7-B045-61B9F3A6975BQ38608906-09DC69D7-49FC-4BE7-8FFF-4DAC8341BD11Q38635119-C7D43DF3-1EE3-4539-8DF1-D62E7D250985Q38689838-FC75DAAC-9FDE-4DC6-B52F-4097DBC0CC6CQ38771936-6F961C4E-EE01-4DCC-A243-8740E5CD69B1Q38826018-BDD99E67-E081-46F4-BC3A-87693F7988E1Q38833873-86F40A9C-FDEE-47B5-8163-638E7DB3037FQ38920435-47CE249B-14EB-4034-A386-42FDCFE40E3BQ39053147-2A89B3D1-3A01-4E03-84B0-7B8CB3971792Q39150632-3872F179-DAD7-4811-9789-A7CB1CD70CFAQ39151466-7337F3F6-D6AE-4ECE-90DD-E6925A06E7A3Q39391610-D49570F8-BE3D-432D-9110-7645E96DD01FQ40559893-9B321F25-12BC-4C5A-8468-AD04CEA30064Q41028325-F802B5BA-D0C1-46E9-AF78-5FA38A7D8915Q41680597-F32AB2C4-BC97-4499-BEEA-2F1E5021D005Q43474417-55E5D67D-FB1E-4E83-AB7A-C7965F919AB1
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Prednisone, lupus activity, and permanent organ damage.
@ast
Prednisone, lupus activity, and permanent organ damage.
@en
type
label
Prednisone, lupus activity, and permanent organ damage.
@ast
Prednisone, lupus activity, and permanent organ damage.
@en
prefLabel
Prednisone, lupus activity, and permanent organ damage.
@ast
Prednisone, lupus activity, and permanent organ damage.
@en
P2093
P2860
P356
P1476
Prednisone, lupus activity, and permanent organ damage.
@en
P2093
Dennis Cotter
Mae Thamer
Miguel A Hernán
P2860
P304
P356
10.3899/JRHEUM.080828
P407
P577
2009-02-04T00:00:00Z